NEW YORK, NY / ACCESSWIRE / November 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

The Boston Beer Company, Inc. (NYSE: SAM)
CONTACT JAKUBOWITZ ABOUT SAM:
https://claimyourloss.com/securities/the-boston-beer-company-inc-loss-submission-form/?id=21033&from=1
Class Period: April 22, 2021 - September 8, 2021
Lead Plaintiff Deadline: November 15, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Boston Beer's hard seltzer sales were decelerating; (2) as a result, Boston Beer was reasonably likely to incur inventory write-offs; (3) the Company was reasonably likely to incur shortfall fees payable to third party brewers; (4) as a result of the foregoing, Boston Beer's financial results would be adversely impacted; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Nano-X Imaging Ltd. (NASDAQ: NNOX)
CONTACT JAKUBOWITZ ABOUT NNOX:
https://claimyourloss.com/securities/nano-x-imaging-ltd-loss-submission-form-2/?id=21033&from=1
Class Period: June 17, 2021 - August 18, 2021
Lead Plaintiff Deadline: December 6, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Nano-X's 510(k) application for the Nanox.ARC was deficient; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the 510(k) application for the Nanox.ARC in its current form; (iii) as a result, NanoX had overstated the Nanox.ARC's regulatory and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Amarin Corporation Plc (NASDAQ: AMRN)
CONTACT JAKUBOWITZ ABOUT AMRN:
https://claimyourloss.com/securities/amarin-corporation-plc-loss-submission-form/?id=21033&from=1
Class Period: December 5, 2018 - June 21, 2021
Lead Plaintiff Deadline: December 23, 2021
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) there was an increasingly high risk that certain of Amarin's patents would be invalidated; (ii) once the District Court invalidated certain of Amarin's patents, there was little to no chance of reversing that ruling; (iii) the Company's litigation was preventing it from effectuating a successful takeover; (iv) Defendants were downplaying the true threat the ongoing abbreviated new drug application litigation posed to the Company's business and future prospects; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law